Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | SRC | P12931 | 7/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.53 |
| ▸ | RET | P07949 | 3/20 | 0.53 |
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | LTK | P29376 | 3/20 | 0.53 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.53 |
| ▸ | FYN | P06241 | 2/20 | 0.53 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.53 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.53 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.53 |
| ▸ | BTK | Q06187 | 2/20 | 0.53 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127833 | 0.89 | EGFR (0.54) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL7128170 | 0.85 | SRC (0.54) | EGFRSRCKDRLCKRET | |
| SCHEMBL7233111 | 0.84 | EGFR (0.60) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL7244628 | 0.84 | EGFR (0.60) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL7235478 | 0.83 | EGFR (0.61) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL7241812 | 0.79 | MAP2K1 (0.56) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL5866417 | 0.78 | EGFR (0.75) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL5866422 | 0.78 | EGFR (0.75) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL3246210 | 0.78 | HDAC1 (0.60) | EGFRHDAC3HDAC1HDAC6SRC | |
| SCHEMBL3240234 | 0.78 | EGFR (0.70) | EGFRHDAC3HDAC1HDAC6SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | claimed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6153617-A | Irreversible bicyclic inhibitors of tyrosine kinases | WARNER-LAMBERT COMPANY (US) | 2000-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885HDAC3 968/4885HDAC1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.